-
Mashup Score: 0
Background Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control in type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, which was designed to assess the efficacy and safety of a novel DPP-4 inhibitor fotagliptin in treatment-naive patients with T2DM. Methods Patients with T2DM were randomized to receive fotagliptin (n = 230), alogliptin (n = 113) or placebo (n = 115) at a 2:1:1 ratio for 24 weeks of double-blind treatment period, followed by an open-label treatment period, making up a total of 52 weeks. The primary efficacy endpoint was to determine the superiority of fotagliptin over placebo in the change of HbA1c from baseline to Week 24. All serious or significant adverse events were recorded. Results After 24 weeks, mean decreases in HbA1c from baseline were -0.70% for fotagliptin, -0.72% for a
Source: bmcmedicine.biomedcentral.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
OBJECTIVE. To evaluate the comparative cardiovascular effectiveness and safety of sodium–glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1
Source: diabetesjournals.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation - 1 year(s) ago
This cohort study compares the incidence of atrial fibrillation in patients with type 2 diabetes associated with use of sodium-glucose cotransporter-2 inhibitors with dipeptidyl peptidase-4 inhibitors or glucagonlike peptide-1 receptor agonists.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 72
Abstract. Type 2 diabetes mellitus (T2DM) is highly prevalent and associated with a two-fold increased mortality, mostly explained by cardiovascular diseases. T
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 11
Abstract. Type 2 diabetes mellitus (T2DM) is highly prevalent and associated with a two-fold increased mortality, mostly explained by cardiovascular diseases. T
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7
AbstractAims. The frequency of an acute increase in serum creatinine (sCr) of >30%, following treatment of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dipeptidyl peptidase 4 inhibitors (DPP-4i) are associated with an increased risk of developing bullous pemphigoid (BP) in patients with diabetes. Autoantibodies targeting epitopes on the processed BP…
Source: Wiley Online LibraryCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 8
Dipeptidyl peptidase-4 inhibitors (DPP-4i) are one of the most widely used antihyperglycemic therapeutic classes in type 2 diabetes mellitus management. In April 2016 & August 2017, the US Food and Drug Administration (FDA) introduced sequential labelling requirements regarding heart failure risk related to DPP-4i. We explored longitudinal trends in prescription of DPP-4i before and after these…
Source: American Journal of CardiologyCategories: CardiologistsTweet-
The Rise & Fall of #DPP4i DPP-4i are the most $$ non-insulin antihyperglycemic therapy in the US. With accelerating CVOT data supporting other classes & select ⚠️HF signals, we finally see fewer new Rx, especially among our highest risk pts. @DLBHATTMD https://t.co/Fqv3DjHDk0 https://t.co/z8GY57nnDV
-
#Fotagliptin, a novel #DPP4i, was non-inferior to active comparator #alogliptin yet superior to #placebo in patients with uncontrolled #type2diabetes A randomized, multicenter, double-blind, placebo-controlled, phase 3 trial from @SunYatsen_Uni https://t.co/Hd1Lbp4l2U https://t.co/hCbwheIC6i